ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA).
As of June 2019, less than 30% (54 out of 181) of applications to the PRIME program have been granted access, and only 20% (one out of five) of ophthalmology applications have been granted access.
“The EMA’s decision to grant PRIME access to sepofarsen further highlights the need for truly groundbreaking medicines to treat LCA10 patients, especially considering the rigorous selection process of the program. In their decision, the EMA mentions several points that support providing sepofarsen access to the PRIME program, including the interim safety and efficacy data from our Phase 1/2 clinical trial that demonstrated meaningful improvements in vision with sepofarsen,”
stated Daniel A. de Boer, CEO of ProQR.
“Looking ahead, our goal is for sepofarsen to reach patients with LCA10 as soon as possible, and access to the PRIME program provides a framework for enhancing our development plans by working closely with the EMA.”
The EMA launched the PRIME program in 2016 to ensure that promising medicines targeting an unmet need have a pathway to accelerate development. The PRIME program is particularly focused on medicines that may provide a therapeutic advantage over existing treatments or that are for indications that currently have no treatment options. To be eligible and accepted for PRIME, a medicine has to demonstrate its potential to benefit patients with unmet medical needs based on early clinical data coupled with non-clinical data.
Through PRIME, the EMA offers additional support to medicine developers including early interaction and dialogue. The program is intended to optimize development plans and expedite the review and approval process so that these medicines may reach patients as early as possible.
This is the first EMA PRIME access that ProQR has been granted for its portfolio of RNA product candidates for inherited retinal diseases, based on promising early data from its lead program in LCA10.